In agreement with its tumor suppressor activity, LOX expression has been reported to be downregulated in many different types of human cancer, such as fibrosarcoma, rhabdomyosarcoma, and melanoma cells (95), lung (96), pancreatic cancer (97), prostate (98), and colorectal cancers (99), which means that LOX expression levels negatively correlate with malignant transformations. Here, LOX is linked to melanoma.